McKesson Corporation $MCK Stock Sold by Legacy Financial Independent Advisors LLC

Key Points

• Legacy Financial Independent Advisors cut its McKesson stake by 81.3% in the third quarter, selling 2,764 shares and retaining 636 shares valued at about $543,000.
• McKesson reported quarterly earnings of $11.68 per share, beating analyst estimates of $10.72, while revenue rose 7.5% year over year to $110.96 billion.
• The company declared a quarterly dividend of $0.94 per share, equivalent to a 0.3% yield. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $1,023.24.

Legacy Financial Independent Advisors LLC cut its position in McKesson Corporation (NYSE:MCK - Free Report) by 81.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 636 shares of the company's stock after selling 2,764 shares during the quarter. Legacy Financial Independent Advisors LLC's holdings in McKesson were worth $543,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of McKesson in the second quarter valued at approximately $8,156,743,000. Bank of America Corp DE acquired a new stake in McKesson during the 2nd quarter worth approximately $998,896,000. Legal & General Group Plc acquired a new stake in McKesson during the 2nd quarter worth approximately $656,566,000. The Manufacturers Life Insurance Company acquired a new stake in McKesson during the 2nd quarter worth approximately $651,462,000. Finally, Bank of New York Mellon Corp bought a new stake in McKesson during the 2nd quarter worth approximately $599,060,000. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Stock Performance

Shares of MCK stock opened at $1,075.38 on Friday. McKesson Corporation has a 52-week low of $723.68 and a 52-week high of $1,121.50. The company has a market capitalization of $125.38 billion, a PE ratio of 27.65, a price-to-earnings-growth ratio of 2.13 and a beta of 0.27. The business's fifty day moving average is $934.72 and its 200 day moving average is $866.92.

McKesson (NYSE:MCK - Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, topping the consensus estimate of $10.72 by $0.96. The business had revenue of $110.96 billion during the quarter, compared to analysts' expectations of $109.90 billion. McKesson had a negative return on equity of 235.48% and a net margin of 1.12%. The firm's revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the business earned $9.86 earnings per share. On average, sell-side analysts forecast that McKesson Corporation will post 44.71 EPS for the current fiscal year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Tuesday, December 1st will be given a dividend of $0.94 per share. The ex-dividend date is Tuesday, December 1st. This represents a $3.76 annualized dividend and a yield of 0.3%. McKesson's payout ratio is presently 9.67%.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: For fiscal Q2 2027, McKesson reported adjusted EPS of $11.68 versus analyst estimates near $10.70, while revenue of about $111 billion also topped expectations and grew roughly 7.5% year over year. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40, citing specialty-drug demand, higher prescription volumes, operating improvements and GLP-1 momentum. The company also completed its $2.25 billion Precision Medicine Group acquisition, expanding its healthcare services footprint. Earnings Call Highlights: Raised Guidance, GLP-1 Momentum
• Positive Sentiment: Several firms raised targets, including TD Cowen, Leerink Partners and Evercore ISI to $1,200; Deutsche Bank raised its target to $1,120. RBC also praised McKesson’s execution, and a Seeking Alpha analysis described normalized earnings as supporting an attractive valuation. TD Cowen Raises Price Target
• Neutral Sentiment: EVP Francisco Fraga sold 600 shares under a pre-arranged trading plan to cover tax withholding on vested equity awards; he retained 5,064 shares, making the transaction less indicative of a change in business outlook. SEC Filing
• Negative Sentiment: RBC’s “sector perform” rating came with a $965 target—below the recent share price—suggesting limited upside in that firm’s view despite its target increase. RBC on McKesson’s Execution

Insider Buying and Selling at McKesson

In other McKesson news, EVP Francisco Fraga sold 600 shares of the business's stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $1,050.00, for a total value of $630,000.00. Following the completion of the transaction, the executive vice president owned 5,064 shares of the company's stock, valued at $5,317,200. The trade was a 10.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO B Jr sold 111 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total transaction of $98,950.95. Following the completion of the transaction, the chief accounting officer directly owned 521 shares in the company, valued at $464,445.45. The trade was a 17.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,812 shares of company stock worth $1,794,182 over the last three months. 0.06% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on MCK. Bank of America increased their price objective on McKesson from $950.00 to $1,050.00 in a report on Thursday, August 6th. TD Cowen increased their target price on shares of McKesson from $1,006.00 to $1,200.00 and gave the stock a "buy" rating in a research note on Thursday. Wells Fargo & Company raised their price objective on McKesson from $812.00 to $933.00 and gave the company an "equal weight" rating in a research note on Tuesday, August 11th. Argus upped their target price on shares of McKesson from $850.00 to $970.00 and gave the stock a "buy" rating in a report on Thursday, September 3rd. Finally, UBS Group lifted their price objective on shares of McKesson from $1,080.00 to $1,200.00 and gave the stock a "buy" rating in a report on Friday, October 16th. Fifteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, McKesson presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,023.24.

About McKesson

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson's principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.